STS Pharm announced today that it has announced the interim outcome of STP0404, a new drug candidate for AIDS treatment at the Keystone Symposia held in Vancouver, Canada, April 24-28 last year.
The Society was established in 1972 and is the most prestigious international society in cancer, new medicines, genetics and molecular biology.
STP0404 is an allosteric integrase inhibitor (ALLINI) that inhibits the non-catalytic active site of HIV integrase in the treatment of AIDS. It is a new candidate for innovative drug that can overcome the limit of drug resistance in existing therapeutic agents, inhibiting the active catalytic sites.
Since 2014, SK Chemicals has been working with Kim Bong-Jin and Son Jong-Chan of the Korea Chemical Technology Research Institute (KCCI) to develop candidate substances.
At this meeting, Estee Palm presented posters and oral presentations of the pre-clinical interim results of STP0404 in a session sponsored by Gilad titled "Functional Cures and HIV Eradication."
In the preclinical stage, STP0404 showed excellent inhibitory effects on several HIV-infected cell lines (PBMC, MT-4, CEMx174) and no cytotoxic effects. In particular, the HIV-1 strain, which is resistant to Raltegravir, a typical inhibitor of the catalase-active integrase site, has excellent inhibitory effect and the possibility of treatment of patients suffering from resistance to raltegravir has been confirmed.
Safety has also been confirmed in repeated studies of oral toxicity in rodents rather than rodents.
In its announcement at the session, STIPHAM also introduced preliminary results and an initial study of new mechanisms to treat AIDS, completely eliminating the ability of HIV viral RNA to be reexpressed in host cells. The study was selected as the National Institute of Health (NIH) project last year and is being conducted jointly with the University of Colorado and the University of Colorado in the United States.
"This announcement confirms the great interest of the participants in the study of new mechanisms for the prevention and safety of AIDS and the excellent inhibitory effects confirmed in the preclinical studies of STP0404," said Estee Palm. "We will do our best to make a successful new first-class drug."
[디지털뉴스국 한경우 기자]
[ⓒ 매일경제 & mk.co.kr, 무단전재 및 재배포 금지]